Related Experiment Video

Updated: Sep 2, 2025

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19
08:48

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19

Published on: February 16, 2022

3.0K

In persons at risk for poor vaccination response or COVID-19 exposure, tixagevimab + cilgavimab reduced COVID-19

Gabriel M Aisenberg1

  • 1University of Texas, Houston, Houston, Texas, USA (G.M.A.).

Annals of Internal Medicine
|August 1, 2022
PubMed
Abstract

Insights

Intramuscular AZD7442, a combination of tixagevimab and cilgavimab, effectively prevented symptomatic coronavirus disease 2019 (Covid-19). This monoclonal antibody treatment provided significant protection against the virus in clinical trials.

Area of Science:

  • Infectious Diseases
  • Immunology
  • Pharmacology

Background:

  • Coronavirus disease 2019 (Covid-19) poses a significant global health threat.
  • Effective prevention strategies are crucial to mitigate the impact of Covid-19.
  • Monoclonal antibodies have emerged as a potential therapeutic and prophylactic option.

Purpose of the Study:

  • To evaluate the efficacy and safety of intramuscular AZD7442 (tixagevimab-cilgavimab) for the prevention of symptomatic Covid-19.
  • To determine the duration of protection offered by AZD7442.
  • To assess the incidence of Covid-19 in participants receiving AZD7442 compared to placebo.

Main Methods:

  • A randomized, double-blind, placebo-controlled clinical trial was conducted.
  • Participants received either intramuscular AZD7442 or a placebo.
  • Symptomatic Covid-19 incidence was monitored over a specified period.

Main Results:

  • AZD7442 demonstrated a statistically significant reduction in the incidence of symptomatic Covid-19.
  • The treatment showed high efficacy in preventing Covid-19 in the studied population.
  • Adverse events were generally mild and comparable between the AZD7442 and placebo groups.

Conclusions:

  • Intramuscular AZD7442 (tixagevimab-cilgavimab) is an effective option for the prevention of Covid-19.
  • This monoclonal antibody provides a valuable tool for Covid-19 prophylaxis.
  • Further research may explore its use in different populations and settings.

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.6K
Optimized Interferon-gamma ELISpot Assay to Measure T Cell Responses in the Guinea Pig Model after Vaccination08:13

Optimized Interferon-gamma ELISpot Assay to Measure T Cell Responses in the Guinea Pig Model after Vaccination

Published on: January 20, 2019

21.8K

Related Concept Videos

Vaccinations01:51

Vaccinations

Overview
45.2K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
650
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
500
Immune Response Against Viral Pathogens01:29

Immune Response Against Viral Pathogens

The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
907
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
1.2K
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
1.2K